- Home
- ZYBT vs LRMR Comparison
ZYBT vs LRMR Comparison
Compare ZYBT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- LRMR
- Stock Information
- Founded
- ZYBT 2004
- LRMR N/A
- Country
- ZYBT China
- LRMR United States
- Employees
- ZYBT N/A
- LRMR N/A
- Industry
- ZYBT
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- LRMR Health Care
- Exchange
- ZYBT NYSE
- LRMR Nasdaq
- Market Cap
- ZYBT 206.2M
- LRMR 183.8M
- IPO Year
- ZYBT 2025
- LRMR N/A
- Fundamental
- Price
- ZYBT $4.97
- LRMR $2.20
- Analyst Decision
- ZYBT
- LRMR Strong Buy
- Analyst Count
- ZYBT 0
- LRMR 10
- Target Price
- ZYBT N/A
- LRMR $19.60
- AVG Volume (30 Days)
- ZYBT 386.8K
- LRMR 919.2K
- Earning Date
- ZYBT 01-01-0001
- LRMR 05-08-2025
- Dividend Yield
- ZYBT N/A
- LRMR N/A
- EPS Growth
- ZYBT N/A
- LRMR N/A
- EPS
- ZYBT 0.06
- LRMR N/A
- Revenue
- ZYBT $26,111,272.00
- LRMR N/A
- Revenue This Year
- ZYBT N/A
- LRMR N/A
- Revenue Next Year
- ZYBT N/A
- LRMR N/A
- P/E Ratio
- ZYBT $87.02
- LRMR N/A
- Revenue Growth
- ZYBT N/A
- LRMR N/A
- 52 Week Low
- ZYBT $3.70
- LRMR $1.93
- 52 Week High
- ZYBT $10.00
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- LRMR 37.86
- Support Level
- ZYBT N/A
- LRMR $2.19
- Resistance Level
- ZYBT N/A
- LRMR $2.44
- Average True Range (ATR)
- ZYBT 0.00
- LRMR 0.18
- MACD
- ZYBT 0.00
- LRMR -0.01
- Stochastic Oscillator
- ZYBT 0.00
- LRMR 35.06
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.